{"name":"CASI Pharmaceuticals, Inc.","slug":"casi-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":43107000,"revenueGrowth":42.9,"grossMargin":40.9,"rdSpend":9748000,"netIncome":-41014000,"cash":47112000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOSXBEVTVxNDNZVUN3cHAzLTZGV0tyd1RERXNOci1NRlVEMVRKNXhDRGJvNjRMZUpZSkJCUDJFWEZkYlJSSUE3NlhLd2ZWaEptMjcxZzcyVkRqYzM2TWNIOURUazE2Zi1uZnFkZkhrLXU2dW9GUXdlY2VuSVVxMlM1bmNOV1A2MXpIS0pRbUl4WmYzWlRoYnZCelluSUVVamhRQTBHYUJleXBlOUNDb01qeXVRR0k2cm5rdVVQcA?oc=5","date":"2026-03-03","type":"pipeline","source":"Stock Titan","summary":"Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan","headline":"Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQOS1jQzBJOEpfZm1GMEtQSTZFd21yQWloU2g2OTFYZFJXVWFEa0RrWGtrZmtad1pLekhvTnhOS0ZhcmVRS2xFbnZVOExlZXl2S01hUXR2Zm85a2RMR3k3djczU3B3RG9JNFdlbTlEMWpKUG1yWmtRSjZ6UUVnTWdGV2xBSU5qdU95ZmdnRnpKZVd3c1VBRVdCVHM5QWE0WEt0Q2U4WHlvXzd4dzJDUE9F?oc=5","date":"2026-02-25","type":"pipeline","source":"Investing News Network","summary":"CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - Investing News Network","headline":"CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNWUxOM0dCT01qOTV5Rjk0Q01mS3ZoazlvT3IxSDBlblpfTm1iOHZZSzVIQ3pURUFfWk0zVS1tNnBmVm83VUdHRU95NDExWjVCRmNlemQ5Y3VUMVNueHZSOC05QUMzeEQ2RlZpNWlxX0hteTRYWjlGbGZIZWFJb3I0RFNHZFZLQkdsSXZmeXVuYkJBQmo4bUdsQ0pDRUlIVzZSR3k1SF9QTVVCeUpIRXNpRENQeU1HWG81WjNNOU5KaWY5MFZWRHdWZ3BfekNjZncyVlBtLXRCQkFEYXdiR1BnN2dldnRuMklNWm10Z2lXVUZBaFVlbHRHeUROMWsxakdrb0E?oc=5","date":"2026-01-12","type":"trial","source":"Investing News Network","summary":"CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Investing News Network","headline":"CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chroni","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQdUozdTlnMm5oLXJGdlRzOFdJTjJaR1pLajNxSVJlMVdGUUhuYTlweURDU0xqLWVwQjhxWXJzellSdWZBYzNWbUF2aDFwY1pLNlZFXzlNc0xJb1JPb0l0Wl9qakFVVnNQZlk2UzFiZFl1ajIwNnp4bFhCSmh5U3JCdjAtTkpleUY0SHNnenFqSncwSGFjVWoxU3JTRWxwNTVwbE1ISENpZ2pZbkRFZ1ZuOUVVa2lMRHFOdlZ5dTZxZFFza01neWlSdUo2c3l0bWpMRk5Bdlp1blV2dXR3Uk1oVVNZV2k1cTR6dm5rYVI2RG5FSGxQTUM5WE5B?oc=5","date":"2025-12-08","type":"regulatory","source":"Investing News Network","summary":"CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting - Investing News Network","headline":"CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hemato","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOWHRQSDViOHBzX0VCS0RVMkNMckNmQV9ncm1FQWxlbm8zemI3Z0d6N244d2ZFM2cwUDNhM29xd3owcHF4S3NnWW1WaTJ6aDBzbk5uX3FWT3djT3ptX2N2blVKMXZVZUhzOF9hOTFQZl84TnJQcFBnX05wbEZsTzFuTWJhMk50Nl9La01YLU1SRFhSeE9TRnZtQktwbDN2S3hxOGlLNG1tbw?oc=5","date":"2025-11-27","type":"pipeline","source":"Investing News Network","summary":"CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network","headline":"CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-09","type":"pipeline","source":"simplywall.st","summary":"One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates - simplywall.st","headline":"One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPcGktdmk4NlFZRUNLZmEyYUpzclBXc05xa1hUcGI2SGVINWRnTzRVRmFVRGgtNzdMemRLUm9BR0hkTVhOQWNFN0VpUUs0eV9ralVELUlFVEx5bEgwMWpzMEJpY2I4S2s5dE43RnBRZ1c0VUhHVy0xZExqRlE2RUZWaW9pOGlXWnFGSXBNcFRLV0lEX25aS1pYTFpKVDVnZUsxRHdKQ3I2ODV2cWRh?oc=5","date":"2025-07-21","type":"pipeline","source":"newswire.com","summary":"CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - newswire.com","headline":"CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNVElVbEZ1Y1FnamhUa2gwQnBtazU5cmc0clgyVWw3eXcxXzBwZDRNemJCTW01Z3pVTEZwWnBPMFNCc3VNZG9LV0lGVEhfakZOcWM3VFVxQ1dDUnN0V3dxTy1qNUZqZlFaZWpVNElLX0NGRGhtZGZ0UXhNdVJlV1lrMWhqUGxFTlQ0ckRyR05rT3QxWnpkQTNVSnpleWFLV3oyV1RISU9DYnV0WXZGZkhjdnlwMGE5Q3dMckE?oc=5","date":"2025-05-12","type":"pipeline","source":"citybiz","summary":"CASI Pharmaceuticals Enters Into Definitive Agreement To Divest Assets in China - citybiz","headline":"CASI Pharmaceuticals Enters Into Definitive Agreement To Divest Assets in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQbFFoeUNNYmJha01COWU4WlJsQXNpRk1Pa0JUamRmT055THNZRkpQWUg0MnZJS0EyRjVtcV85SGladHhXNWZFbENxcEZUWmtHaDNIeTFiVnNqVk9nTTU5blVpRnV6Um1zSlA1c1d4TFgtZ3FjSTJqeFJiWGl4RU5fSTZfTHlvVllhMm9iQ3c2S1pVbG5TU1JvRGdmdE9lTlR0d0lydzZhWk9OTndyTjJtN3NQRm4wd0FEbDZnd2dOSXlMZFZHUWptVTZVYw?oc=5","date":"2024-07-08","type":"pipeline","source":"PR Newswire","summary":"CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PR Newswire","headline":"CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQVlg3TXRablgtdlFhU1RVa3B4XzJjeGZvaW1OMkUwZTllbldSdjU0NHdWZ0dMVXFqMTZQeVlCRXUtSFdBRi04RUNwU1E2cjJkQWNxcm1DeGpPbk44MUx0Q00yNWZac29VQ1FnNFZMVTNJaGdxMHIzVFJzOEs3bldmVmIxZ3ZlUzVsSXY5SnpxRlZsUEMyQVl2RVBwT3c5RVBDVUMyYzBpbWV6T0pna295OXhUckZzZnJ5Z24yZVVfcU1tZHFQb2VZVEs2QUVuOGNQM1J6RWJPN2V1ckc3eGYyNE9mZmRFYnkzcVgzTVdYekVFTERwdnVrZy1fRlI0TDlUWmNaNXJnV1pVSzR4VE0tbE85SkE1c1N6SWp3bTRjX3E5djVGdG1ZcC01dUZrWkI1bVJqM05ORzVJUQ?oc=5","date":"2024-06-26","type":"deal","source":"PR Newswire","summary":"CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He - PR Newswire","headline":"CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-26","type":"deal","source":"PR Newswire","summary":"CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business","headline":"CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOaU42RHpVcjZTUmxWVE03TjM5cC1LX19DTWswb3NxcWdRdklsYXBMR1ZtWHhLQUNES091RlVaR3ppOUN6ak9nUVM3d3ZHZkMwUzh6ZGlaZzRfZnlscXlWeFk0QjRXV1pELUpNMW9GRVdSb0JjY0tITEVMdmtxQ254aUZtSGZrazlmcjd6QmY0SzhMMFJGcXhYOGVWZWxmWUJUdXlYS1Iyck96SThzNUNOcXZLbnNuSTBzNjBCMW1kT1N5WjB0UFpIS2JKRy1Uekd1RUJHTDg5ZThpa19WUGdRWWJTQkZsYk83Rm9paFE1RXI1U2xPLUFVczdvSzZsUQ?oc=5","date":"2023-07-20","type":"deal","source":"PR Newswire","summary":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 - PR Newswire","headline":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339","sentiment":"neutral"},{"date":"2023-03-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-01-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2022-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":43107000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":43107000,"period":"2022-12-31"},{"value":30168000,"period":"2021-12-31"},{"value":15141000,"period":"2020-12-31"},{"value":4131000,"period":"2019-12-31"},{"value":0,"period":"2018-12-31"},{"value":0,"period":"2017-12-31"}],"grossProfit":17611000,"grossProfitHistory":[],"rdSpend":9748000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-41014000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":47112000,"cashHistory":[],"totalAssets":96234000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}